New enhancements have been made by Charles River Laboratories to its digital pathology solution, providing a next-generation AI-driven end-to-end workflow solution that is designed to enhance the efficiency of nonclinical research by cutting down nonclinical study timelines by at least one week. The enhanced Charles River digital pathology solution facilitates the inclusion of AI capabilities within the histology and pathology processes, allowing nonclinical study timelines to be shortened without affecting GLP compliance. This new digital pathology solution utilizes a fully integrated histology LIMS, quality assurance through AI pathologist evaluation of slides, validated digital pathology reading workflow, and automation of workflow process management. This new digital pathology platform will streamline the Charles River pathology group’s digital operations, enabling tighter centralized collaboration across one of the company’s global pathology networks, Much reducing the number of physical slides transported around the globe; and expand pathologist productivity by providing AI decision support tools and effective anomaly detection.
Also Read: Revolutionizing Oncology: Ataraxis AI Debuts First-in-Class Predictive Tool for Personalized Breast Cancer Treatment
Finally, Charles River highlighted its ability to enable the wider use of Virtual Control Groups (VCGs) to allow further reductions in the number of control animals used, while maintaining scientific rigor. Danielle Brown, Digital Products Leader at Charles River, said, “Digital pathology isn’t just about digitizing slides; it is about reengineering the entire workflow.” The declaration is indicative of the expanding use of AI within digital pathology as pharma and biotech companies continue to utilize intelligent automation to perform more accurate diagnostics, hasten toxicology studies and streamline research efficacy. Industry Analysts predict that innovations like these could further fuel the growth of the global digital pathology market and as company estimates, such trends bode well with industry focus on precision medicine, AI-enabled diagnostics and data-driven drug development pathways. With today’s announcement, Charles River is cited as continuing as a leader within the future of AI-enabled pathology and its promise for life sciences establishments to hasten research timelines, while enhancing scientific insight and operational scalability.
